Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia

Bone Marrow Transplantation

Volumn 24, Issue 3, 1999, Pages 345-348

  Galimberti, S ^a   Papineschi, F ^a   Carmignani, A ^b   Testi, R ^a   Fazzi, R ^a   Petrini, M ^a,c  

^a UNIVERSITY OF PISA   (Italy)

^b AOP   (Italy)

^c Divisione di Ematologia   (Italy)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic; Bone marrow transplantation; Chemoresistance

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CASE REPORT; HUMAN; MALE; PRIORITY JOURNAL; SEPSIS; SKIN NECROSIS;

EID: 0032792110     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701875     Document Type: Article

References (22)

1. Bennett JM, Catowsky D, Dainer MT et ai Proposal for the classification of the acute leukemias. FAB Co-operative Group. Br J Haematol 1976; 33: 451-458.
2. Spremolla G, Gori Z, Bottone E. Electron microscopy and cytochemistry of the bone marrow in acute promyelocytic leukaemia. Haematologica 1976; 61: 202-218.
3. Barbui T, Finazzi G, Falanga A. The impact of all-trans retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 3093-3102.
4. Larson RA, Kondo K, Vardiman JW et al. Evidence for a 15:17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76: 827-841.
5. Kakizutka A, Miller WH, Umesono K et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66: 663-674.
6. Degos L, Dombert H, Chomienne C et al. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-2653.
7. Bernard J, Weil M, Boiron M et al. Acute promyelocytic leukemia. Results of treatment with daunorubicin. Blood 1973; 41: 489-496.
8. Avvisati G, Mandelli F, Petti MC et al. Idarubicin (4-dimethoxidaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukaemia. A pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990; 44: 257-260.
9. Huang ME, Yu-Chen Y, Shu-Rong C et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
10. Castaigne S, Chomienne C, Daniel MT et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I Clinical results. Blood 1990; 76: 1704-1709.
11. Degos L, Chomienne C, Daniel MT et al. Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid. Lancet 1990; 2: 1440-1441.
12. Warrel RP Jr, Frankel SR, Miller WH Jr et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New Engl J Med 1991; 324: 1385-1393.
13. Sun G, Ouyang R, Chen S et al. Follow-up of 481 patients with APL after CR using ATRA. Chin J Hematol 1994; 15: 411-415.
14. Fenaux P, Le Deley MC, Castaigne S et al. The European APL 91 Group. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241-3249.
15. Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans retinoid acid + idarubicin) in newly diagnosed acute promyelocytic leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398.
16. Mandelli F. New strategies for the treatment of acute promyelocytic leukaemia. J Int Med 1997; 242 (Suppl.740): 23-27.
17. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
18. Magrath IT, Janus C, Edwards BK et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984; 63: 1102-1111.
19. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl J Med 1998; 339: 1341-1348.
20. Gianni M, Koken M, Chelbi-Alix MK et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic resistant NB4 cells. Blood 1988; 91: 4300-4310.
21. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353.
22. Wang ZG, Rivi R, Delva L et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998; 92: 1497-1504.